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Abstract
Vascular smooth muscle (VSM) growth is integral in the pathophysiology of blood vessel diseases,
and identifying approaches that have capacity to regulate VSM growth is critically essential. Cyclic
nucleotide signaling has been generally considered protective in cardiac and vascular tissues and has
been the target of numerous basic science and clinical studies. In this project, the influence of BAY
41-2272 (BAY), a recently described soluble guanylate cyclase (sGC) stimulator and inducer of
cyclic guanosine monophosphate (cGMP) synthesis, on VSM cell growth was analyzed. In rat A7R5
VSM cells BAY significantly reduced proliferation in dose- and time-dependent fashion. BAY
activated cGMP and cyclic adenosine monophosphate (cAMP) signaling evidenced through elevated
cGMP and cAMP content, increased expression of cyclic nucleotide-dependent protein kinases, and
differential vasodilator-stimulated phosphoprotein (VASP) phosphorylation. BAY significantly
elevated cyclin E expression, decreased expression of the regulatory cyclin-dependent kinases
(Cdk)-2 and -6, increased expression of cell cycle inhibitory p21WAF1/Cip1 and p27Kip1, and reduced
expression of phosphorylated focal adhesion kinase (FAK). These comprehensive findings provide
first evidence for the anti-growth, cell cycle-regulatory properties of the neoteric agent BAY 41-2272
in VSM and lend support for its continued study in the clinical and basic cardiovascular sciences.
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Introduction
Abnormal growth of vascular smooth muscle (VSM) provides an etiologic underpinning of
many forms of cardiovascular disease (CVD) and has been historically targeted for therapeutic
intervention. Our laboratories [1,2] and others [3,4,5] have identified cell cycle-related proteins
including protein kinases, G1 cyclins, cyclin-dependent kinases (Cdks), and Cdk inhibitors
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(CKIs) as integral mediators of VSM growth under in vitro and in vivo settings. Cyclin/CDK
complexes play pivotal roles in regulating G0/G1-to-S phase progression while CKIs inhibit
cyclin/CDK activity and lead to static G1 arrest.
Cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) are
critically important second messengers with wide-ranging roles in VSM. Our previous findings
provide strong evidence that cGMP-generating heme oxygenase (HO)/carbon monoxide (CO)
signaling has capacity to reduce abnormal VSM growth through anti-proliferative and pro-
apoptotic mechanisms [1,6,7,8,9]. Of particular interest we found that exogenous CO is capable
of reducing neointimal development through reduction in cyclins A and E and transforming
growth factor (TGF)-?1 signaling but without marked effects on cyclin D1 or p21WAF1/Cip1
and p27Kip1 [1].
A family of synthetic soluble guanylate cyclase (sGC) agonists has been identified and
characterized over the past 15 years that is rapidly gaining interest in terms of scientific utility
[6,9,10]. The prototype, a benzyl indazole termed YC-1, has been shown to confer protection
to cardiovascular and hematological tissues [11,12,13,14]. BAY 41-2272 (BAY), a recently
described pyrazolopyridine derivative and “second-generation” YC-1 mimetic, is an attractive
agonist for NO- and/or CO-mediated signaling [15,16,17]. BAY possesses anti-hypertensive
[18] and anti-platelet [19] properties and reduces load during experimental heart failure [20],
yet the influence of BAY on VSM growth has not been documented to date. Therefore, the
overall goal of this project is to characterize the influence of BAY on VSM cell growth.
Methods
This investigation abided by guidelines of the Institutional Animal Care and Use Committee
and conformed to the Guide for the Care and Use of Laboratory Animals (U.S. National
Institutes of Health, Publication No. 85-23, revised 1996).
Vascular smooth muscle cell culture
Rat thoracic aorta A7R5 VSM cells (ATCC, Manassas, VA) were cultured in Dulbecco's
Modified Eagles Medium (DMEM) supplemented with fetal bovine serum (FBS, 0.2-10%), 2
mM L-glutamine, 500 U penicillin, and 100 mg/L streptomycin at 37 °C in 95% air/5% CO2.
Cells were serially split and used through passage 6.
Cell proliferation assays
Three approaches were used to measure cell growth: hemacytometry, automated cell counting
(Vi-Cell, Beckman Coulter), and fluorescent nucleic acid staining (CyQUANT Cell
Proliferation Assay; Molecular Devices, Sunnyvale, CA) [21]. In general, cells were plated in
multi-well plates (25,000 cells/well in 24-well plates) in 10% FBS until adherent, quiesced in
low serum (0.2% FBS) conditions overnight, and then growth-stimulated with 10% serum in
DMEM and varying concentrations of BAY with/without the following agents: the heme
substrate and HO inducer hemin (20 ?M) [22], the HO inhibitor tin protoporphyrin-IX (SnPP-
IX; 20 ?M) [23], the NO donor sodium nitroprusside (SNP; 1 mM) [24,25], or the NO synthase
inhibitor L-NAME (20-2000 ?M). At specific times cells were trypsinized (0.5%, 3-4 minutes,
37 °C) and whole cell suspensions were prepared for use in specific assays. For the fluorescent
assays, standard curves were prepared for extrapolation of random units into cell numbers.
Trypan blue exclusion staining
To estimate viability, trypan blue exclusion staining was performed in parallel with each
proliferation assay. Cells were trypsinized (0.5%, 3-4 min, 37 °C) and suspensions were
incubated with 0.4% trypan blue (1:1, 2 min, MediaTech CellGro). Numbers of stained cells
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and total (stained and unstained) cells were counted and viability determined as the percentage
of unstained cells.
ELISA for cGMP and cAMP
Cyclic GMP and cAMP levels were measured using CatchPoint Assays and a Spectra Max
Gemini EX microplate reader (Molecular Devices). Briefly, VSM cells were pre-treated with
0.75mM IBMX (Calbiochem) in dimethyl sulfoxide (DMSO) for 10 min. BAY/DMSO
treatments were added for specific times (? 60 min), after which reactions were stopped with
lysis buffer. Protein concentrations were determined with a BCA protein assay kit (Pierce).
Results were calculated with SoftmaxPro software (Molecular Devices).
Western blot
Cells were lysed in buffer (50mM Tris, pH 6.8; 1% SDS; 0.1% Triton; protease inhibitor
cocktail (Roche); phosphate inhibitor cocktail (Santa Cruz)) and sonicated on ice followed by
centrifugation (14000g, 20 min). Protein concentration of whole cell lysates was determined
by the BCA assay (Pierce). Proteins were separated on SDS-PAGE gels and transferred to
Immobilon-P membranes (Millipore) using Mini-Protean Electrophoresis and Mini Trans-Blot
Cells (Bio-Rad). Blots were blocked with 5% non-fat milk in TTBS (25mM Tris/Tris-HCl;
0.0027M KCl; 0.13M NaCl; 0.1% Tween 20) or 5% BSA in TTBS for 1 hour and incubated
with primary antibodies directed against sGC?1 and sGC?2 (1:500; Santa Cruz), protein kinase
G (PKG) and protein kinase A (PKA) (1:1000; Abcam), phospho-PKASer338 (1:1000;
Biosource), VASP, phospho-VASPSer157, and phospho-VASPSer239 (1:1000; Cell Signaling),
cyclins A, D1, and E and p27Kip1 and p21WAF1/Cip1 (1:200; Santa Cruz), Cdk-2 and Cdk-6
(1:1000; Millipore), FAK and phospho-FAKTyr397 (1:500), apurinic/apyrimidinic
endonuclease/redox factor 1 (APE/Ref1; 1:500), ?-tubulin (1:1000; Sigma), and GAPDH
(1:400; Santa Cruz) overnight at 4 °C. Blots were washed with TTBS, incubated with
peroxidase-linked secondary antibodies (1:5000) for 1 hour, visualized using Pierce ECL
Western blotting kit, documented using an Alpha Imager 2200, and analyzed with ImageJ 1.40g
software (NIH).
Statistical analyses
Data were stored and analyzed on personal computers using Excel 2007 (Microsoft) and Sigma
Plot 10.0 and Sigma Stat 3.1 (SPSS, Inc.). One-way analysis of variance (ANOVA) and post-
hoc Holm-Sidak multiple comparison tests were used to detect changes between individual
cohort groups [26]. Data are expressed as mean ± SEM, and a P < 0.05 was considered
statistically significant.
Results
The three approaches used to measure cell growth yielded consistent and reproducible results
within each cohort and across multiple experiments (see Table). In summary, treatment of VSM
cells with BAY (0.001-100 ?M) in 10% FBS for 48 or 72 hours resulted in significant (p < .
001) dose-dependent reduction in cell numbers (results from fluorescent nucleic acid staining
72 h post-treatment are shown in Fig. 1A). Not surprisingly, detectable differences in
proliferation from BAY treatment were not detected after 24 hours (an estimated cell cycling
time for VSM cells is ᙺ22 hours). In effort to examine upstream involvement by the HO/CO
pathway, concomitant treatment of cells with BAY and the HO inducer hemin (20 ?M) caused
significantly lower cell numbers (p = .026) at each BAY concentration than that observed with
BAY alone (Fig. 1B). In corresponding fashion, HO inhibition by 20 ?M SnPP-IX reversed
BAY-induced growth inhibition and led to significantly increased cell numbers (p = .022)
compared to sole BAY treatment (Fig. 1B). Likewise, simultaneous exposure of cells with
BAY and the NO donor SNP (1.0 mM) exhibited a trend (not statistically significant) for
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reduced cell numbers at each BAY concentration compared to BAY alone; however,
concomitant BAY and the NO synthase inhibitor L-NAME (20-2000 ?M) failed to noticeably
alter cell growth compared to exclusive BAY treatment (data not shown). Combined BAY with
hemin and SNP did not noticeably alter cell growth compared to the BAY and hemin or BAY
and SNP cohorts, respectively. Trypan blue exclusion staining run in parallel with each assay
within each cohort did not reveal statistically significant reduction in viability in any treatment
group (baseline: 87.5 ± 12.4%; 0.001 ?M BAY: 78.2 ± 16.5%; 100 ?M BAY: 66.8 ± 22.3%
(p = .17)).
Ensuing studies analyzed the sGC/cGMP/cAMP-specific actions of BAY in VSM cells. BAY
41-2272 approximately doubled the content of cGMP (23,421 vs. 10,357 nM/mg protein) and
cAMP (10,500 vs. 5607 nM/mg protein) compared to vehicle-treated cells between 10 and 30
min incubation without significant effects on protein expression of sGC?1 or sGC?2 over 4
hours (data not shown). Western analyses of cyclic nucleotide-dependent protein kinases
showed that BAY (0.001-10 ?M) had minimal effect on total PK-G but increased expression
of PK-A (60%) and phosphorylated (at Serine 338) PK-A (40%; p = .08) after 24 hours (Fig.
2). Using differential VASP phosphorylation as a biochemical marker for activated kinase
signaling in VSM [27,28], with Ser239 phosphorylation primarily indicative of a PK-G event
and Ser157 phosphorylation predominantly PK-A-mediated (although Ser157 can also be
phosphorylated by PK-G) [29,30,31,32], BAY did not alter total VASP content but increased
VASPSer239 (ᙺ40%) and more than doubled VASPSer157 after 24 hours (Fig. 3).
The influence of BAY on recognized VSM cell cycle-regulatory factors was then investigated.
Figure 4 shows that BAY increases expression of cyclins A (ᙺ80%) and D1 (ᙺ50%) and
significantly cyclin E (p < .05) after 48 hours. At this time point BAY significantly reduced
expression of Cdk-2 (p < .05) and Cdk-6 (p < .001; Fig. 5) and significantly increased protein
expression of the cell cycle-inhibitory p27Kip1 (p < .001) and p21WAF1/Cip1 (p < .05; Fig. 6).
In these experiments, verification of the nuclear fraction was verified in each sample by
stripping and re-probing for nuclear-specific APE/Ref1, a key protein in the base excision
repair pathway (data not shown). Lastly, BAY did not alter total FAK but significantly reduced
expression of phosphorylated (at Tyrosine 397) FAK (Fig. 7).
Discussion
This study provides the first scientific evidence for the anti-growth properties of the recently
characterized sGC stimulator BAY 41-2272 in VSM and offers insights into its cell cycle-
regulatory mechanisms of action. In rat A7R5 VSM cells BAY significantly inhibited serum-
induced growth which was directly influenced by upstream HO and NO signaling. BAY
stimulated VSM cGMP and cAMP signaling, including downstream kinases and VASP,
markedly reduced cell cycle-regulatory Cdks and FAK, and increased cell cycle inhibitory
CKIs p27 and p21 therefore leading to static G1 arrest. These novel results provide compelling
support for the biologic relevance of BAY as an anti-mitogenic agent in VSM, offer promise
for its therapeutic utility under conditions of cardiovascular adversity, and provide sound
foundation for continued investigation of this attractive compound.
In this study BAY dose-dependently inhibited serum-induced VSM cell growth. Notably, this
is the first report documenting growth-inhibitory effects of BAY in VSM. These findings
corroborate earlier results by our laboratory [11,12,13] and others [33] demonstrating anti-
mitogenic effects of the BAY archetype YC-1 in VSM and provides further support for the
therapeutic utility of this promising class of sGC stimulators. Reliance of BAY on upstream
HO/CO signaling was also observed, indicating that BAY, a cyclase agonist, operates more
effectively in the presence of the activating gaseous ligand CO. This is therapeutically
significant, as CO as well as NO signaling is induced during injury-mediated vascular growth
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[11]. Another notable aspect of these data is that, in the absence of BAY, induced HO signaling
caused approximately a 70% reduction in growth while HO inhibition resulted in a ᙺ40%
increase in growth, demonstrating the importance of HO/CO signaling (in the absence of BAY-
mediated sGC stimulation) on cellular growth and confirming some of our earlier findings.
Adding to its therapeutic attraction, cytotoxicity analyses failed to reveal discernable reduction
in viability from BAY in any treatment group, suggesting that BAY operates via cytostatic
rather than cytotoxic action.
These unique data demonstrating anti-mitogenic effects of sGC stimulation by BAY in VSM
are complimented by similar studies in diverse tissues. Soluble GC stimulation by BAY has
been shown to reduce proliferation of rat mesangial cells through cyclic GMP-dependent
[34] and cyclic AMP-dependent [35] processes, lending credibility for the clinical utility of
BAY against renal proliferative disorders. Paradoxically, in vascular endothelial cells sGC
activation by BAY [36] or cyclic GMP/PK-A induction by phosphodiesterase (PDE) inhibition
[37] leads to enhanced growth and promotion of angiogenesis, and these are theorized to occur
through both cyclic GMP-dependent and cyclic GMP-independent pathways [38]. This is of
particular significance as choice therapies against vascular proliferative diseases should
incorporate both mitigation of VSM proliferation and enhancement of reparative vascular
endothelial growth.
Acute exposure of VSM cells to BAY stimulated cyclic nucleotide signaling, observed through
increases in cGMP and cAMP, elevated cGMP/cAMP-directed kinases, and activation of the
kinase target VASP, thus confirming bioactivity of BAY in cultured VSM. Not surprisingly,
as a sGC stimulator BAY directly induced the cGMP system, in accordance with our earlier
findings using the parent compound YC-1 in cultured VSM cells [12]. These values,
nonetheless, are markedly lower than those reported in isolated ovine pulmonary [39] and
mouse femoral [40] arteries and rat brain stem vasculature [41]. Indeed, preliminary data in
rat primary arteries (data not shown) reveal much higher cGMP levels after 30 min incubation
with BAY, suggesting that cGMP stimulation by BAY may be reduced in cell lines versus
primary preparations and/or may be largely contextual and based on experimental conditions.
Caution is thus warranted when extrapolating data derived from in vitro studies to the in vivo
environment. Specifically in terms of cyclic nucleotide biology, a potential limitation of this
extrapolation would be an under-estimation of their physiological significance in the intact
body. This caveat also argues for continued studies aimed at analyzing these phenomena in
primary tissues.
Additionally, a remarkable aspect of these data is that BAY has clear capacity to activate the
parallel cAMP cascade. Doubling of cAMP by BAY has been reported in a human leukemia
cell line [42], yet other studies have failed to show discernable effects of BAY on cAMP in rat
brain stem [41] or rabbit isolated perfused atria [43]. Findings from our latest article suggest
that YC-1 operates through sGC and cyclic GMP to activate the cyclic AMP pathway in order
to induce upstream NO signaling [44]. BAY 41-2272 may operate via a similar mechanism
although this mandates further study. Cyclic GMP has capacity to directly stimulate cyclic
AMP/PK-A [45] and inhibit cyclic AMP-specific phosphodiesterase [46], and it was recently
proposed in a study examining vascular relaxation in murine PK-G-deficient tissues that cGMP
operates primarily through PK-A in VSM [28]. Moreover, YC-1 can operate through cAMP-
mediated signals [47]. Nonetheless, this is the first report documenting ability of BAY to
increase cAMP and to activate cAMP signaling in VSM. In fact, these combined results (larger
increases in PK-A and PSer338-PK-A compared to PK-G, markedly greater increases in
PSer157-VASP compared to PSer239-VASP) strongly suggest that BAY preferentially activates
cAMP signaling secondary to sGC stimulation, yet further studies are needed, perhaps in
primary preparations, to verify these observations.
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In mammalian VSM cell cycle division, progression through G1 and entry into the S phase is
rate-limiting and is regulated by formation and activation of cyclin/Cdk complexes, and
endogenous CKIs inactivate these complexes and leads to G1 arrest [3,48]. Early G1 is largely
governed by cyclin D/Cdk-2, -4, or -6, and at this stage p21 and/or p27 can bind and exert cell
cycle inhibition. Cyclin E/Cdk2 accumulates during late G1 and triggers passage into S phase,
during which cyclin A/Cdk2 levels increase and provoke G2 transition. Exciting results from
this study show that, although BAY increases cyclin expression and in particular cyclin E,
BAY significantly reduces catalytic Cdk expression and markedly elevates the Cdk-inhibitory
CKIs p27 and p21. Direct correlation between over-expression of p27/p21 and growth
inhibition in VSM substantiates earlier findings in pig VSM [3] and suggests that the
mechanism of BAY-mediated growth reduction in rat VSM involves p21/p27-mediated cyclin/
Cdk inhibition. Similar results that cAMP and not cGMP is associated with p27 upregulation
during VSM growth inhibition have been reported in human VSM cells [49]. Additionally, we
show that BAY reduces phosphorylated FAK at Tyrosine 397, its major auto-phosphorylation
site and the binding site for the SH2 domain of Src tyrosine kinase in an essential step for FAK
activation. FAK-mediated actin dynamics are critically involved in the ability of cells to
proliferate, and reduction in FAK activation is considered growth-inhibitory. Furthermore,
these findings support results from a recent study that suggest cAMP inhibits VSM cell
proliferation through the p27-related kinase Skp2 along with reduction in PTyr397-FAK [50].
Of note, these studies were performed using commercial A7R5 VSM cells. In general, cell
lines may not accurately reproduce the in vivo milieu that exists in primary preparations or
whole animals, and phenotypic alterations have been suggested for commercial or serially-
passaged cell lines. Thus, verification of these findings in primary VSM cells or in whole animal
models is warranted for rigorous interpretation. Nonetheless, A7R5 VSM cells represent a
valuable model with which to initially examine the VSM response to experimental intervention.
Conclusion
In summary, this is the first report documenting anti-growth properties of the sGC stimulator
BAY 41-2272 in VSM and offers biologically relevant mechanisms for this promising
therapeutic agent. BAY inhibited growth of rat VSM cells in a manner influenced by upstream
HO and NO signals. Mechanistically, results suggest that BAY operates primarily through
cAMP signaling leading to cytostatis via reduced Cdks and FAK and enhanced CKI
involvement. These original findings provide compelling initial evidence for therapeutic
significance of BAY as growth-inhibitory agent in VSM cells and offer promise for continued
study of its pharmacological efficacy in cardiovascular disorders.
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Figure 1.
A: Incubation of rat A7R5 VSM cells with BAY 41-2272 (0.001-100 ?M) in 10% FBS
significantly (p < .001) reduces cell growth in dose-dependent fashion after 72 hours as
measured with fluorescent nucleic acid staining. Comparable growth-inhibitory effects of BAY
were observed using hemacytometry and automated cell counting (data not shown). Results
are mean ± SEM, and n = 3 experiments/group. *Statistically significant with p < .05,
***statistically significant with p < .001 versus normalized DMSO vehicle controls. B:
Concomitant treatment of cells with BAY and the HO inducer hemin (20 ?M) significantly
reduced cell numbers (p = .026) at each BAY concentration while HO inhibition by tin
protoporphyrin-IX (SnPP-IX; 20 ?M) significantly increased cell numbers (p = .022) compared
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to exclusive BAY treatments. Post-hoc results: *statistically significant with p < .05,
**statistically significant with p < .01, ***statistically significant with p < .001 versus BAY
41-2272 treatment only. Trypan blue exclusion staining did not reveal significant reduction in
cell viability in any treatment group (data not shown). Results are mean ± SEM, and n = 3
experiments/group.
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Figure 2.
Effects of BAY 41-2272 on cyclic nucleotide-regulated protein kinases in VSM. A: Western
blot showing expression of PK-G, PK-A, and phosphorylated PK-A (at Serine 338) following
24 hours of BAY treatment. B-D: Densitometry (normalized to ?-tubulin) reveals that BAY
has minimal effect on PK-G but increases PK-A (ᙺ60%) and phosphorylated PK-ASer338
(ᙺ40%; p = 0.8). Results are mean ± SEM, and n = 5-6 experiments/group.
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Figure 3.
Effects of BAY 41-2272 on VSM VASP after 24 hours. A: Western blots for total VASP and
phosphorylated VASP (at Ser157 and Ser 239). B-D: Densitometry (normalized to ?-tubulin)
shows that BAY has no discernable effect on total VASP but markedly increases
VASPSer157 (ᙺ140%; p = .17) and VASPSer239 (ᙺ40%) in dose-dependent fashion. Results are
mean ± SEM, and n = 1 experiment for VASP and n = 6 experiments/group for phosphorylated
VASP.
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Figure 4.
Effects of BAY 41-2272 on nuclear cyclin expression in VSM after 48 hours incubation. A:
Western blot showing protein expression for the G1 cyclins A, D1, and E. B-D: Densitometry
(normalized to nuclear GAPDH) reveals that BAY (0.001-10 ?M) elevates expression of
cyclins A (ᙺ80%) and D1 (ᙺ50%) and significantly increases cyclin E (ᙺ200%; p = .015).
Concomitant staining for APE/Ref1 verified nuclear localization of all samples (data not
shown). Results are mean ± SEM, and n = 5 experiments/group. Post-hoc results: *statistically
significant versus DMSO controls with p < .05.
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Figure 5.
Effects of BAY 41-2272 on VSM nuclear Cdk expression after 48 hours. A: Western blot
showing Cdk-2 and Cdk-6 expression. B-C: Densitometry (normalized to ?-tubulin) shows
that BAY significantly and dose-dependently reduces expression of Cdk-2 (ᙺ35%; p = 0.031)
and Cdk-6 (ᙺ60%; p < .001). Post-hoc results: *statistically significant with p < .05;
**statistically significant with p < .01. Concomitant staining for APE/Ref1 verified nuclear
localization of all samples (data not shown). Results are mean ± SEM, and n = 4 experiments/
group.
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Figure 6.
Effects of BAY 41-2272 on the nuclear cyclin-dependent kinase inhibitors (CKIs) p27Kip1 and
p21WAF1/Cip1 after 48 hours incubation. A: Western blot showing p27 and p21 induction by
BAY. B-C: Densitometry (normalized to nuclear GAPDH) shows that BAY significantly
increases p27 expression (> 60%; p < .001) and approximately doubles p21 expression (p = .
02). Post-hoc results: *statistically significant with p < .05; **statistically significant with p
< .01. Concomitant staining for APE/Ref1 verified nuclear localization of all samples (data
not shown). Results are mean ± SEM, and n = 5 experiments/group.
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Figure 7.
Effects of BAY 41-2272 on VSM FAK after 72 hours. A: Western blot for FAK and
phosphorylated FAK (at Tyrosine 397). B-C: Densitometry (normalized to ?-tubulin) shows
that BAY has minimal effects on total FAK but significantly (p < .001) reduces phosphorylated
FAK. Post-hoc results: *statistically significant with p < .05 versus DMSO controls;
*statistically significant with p < .01 versus DMSO controls. Results are mean ± SEM, and n
= 2 for FAK group and n = 4 for phosphorylated FAK group.
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